Project description DEENESFRITPL The devil is in the details when it comes to monoclonal antibody production Monoclonal antibodies (mAbs) enlist natural immune system functions to fight diseases. They are produced in vitro using tissue-culture techniques to generate highly specific antibodies from a single immune cell clone. The desired mABs are harvested periodically and purified from the medium in an expensive and time-consuming process. However, tissue culture and purification can have detrimental impact on antibody glycosylation (addition of a carbohydrate), a critical post-translational modification related to the safety and clinical efficacy of therapeutic antibodies. PATGlycoPrint is developing a novel platform to detect glycosylation quickly and reliably in samples from both tissue culture and from purified mABs. If successful, it could revolutionise the production of mABs with benefits for the pharmaceutical industry and patients alike. Show the project objective Hide the project objective Objective Glycosylation of therapeutic antibodies is one of the most critical quality attributes (CQAs) in biopharmaceutical manufacturing because of its strong impact to the treatment efficacy. Many parameters in the production process including upstream cell culture and downstream purification can significantly change the antibody glycosylation profiles. Therefore, monitoring and quality controlling of glycosylation is central to ensure high quality and consistent products. Unfortunately, this requires advanced analytical equipment and procedures that are expensive and time consuming and not suitable for on-line applications. Process analytical technologies that enable real-time monitoring of glycosylation during the production process would thus be a game changer in the biopharma industry. The aim of this research action is to develop and evaluate a new process analytical technology based on an innovative nanoplasmonic glycan-binding array that can detect the glycosylation patterns of downstream and upstream samples immediately or in a few minutes, respectively. The proposal is established to support the experienced researcher (ER), who wish to resume research in Sweden after a career break, and to enhance the ER´s employment opportunities in both academic and industrial sectors by an extensive two-way exchange of knowledge between the host and the ER as well as innovation and networking opportunities. The research project includes different branches of knowledge including biosensors, nanomaterials, biomanufacturing, analytical chemistry as well as surface, organic and peptide chemistry. In line with the MSCA-2018 Work Programme, this broad interdisciplinary training is expected to diversify the ER competence and greatly impact the ER’s future career while developing and exploring new technologies that can dramatically improve current strategies for bioproduction. Fields of science natural scienceschemical sciencesanalytical chemistryengineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsbiosensorsnatural sciencesbiological sciencesbiochemistrybiomoleculesengineering and technologynanotechnologynano-materialssocial scienceseconomics and businessbusiness and managementemployment Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2018 - Individual Fellowships Call for proposal H2020-MSCA-IF-2018 See other projects for this call Funding Scheme MSCA-IF-EF-CAR - CAR – Career Restart panel Coordinator LINKOPINGS UNIVERSITET Net EU contribution € 203 852,16 Address Campus valla 581 83 Linkoping Sweden See on map Region Östra Sverige Östra Mellansverige Östergötlands län Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
